Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $10.80 Consensus Price Target from Analysts

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) has been assigned a consensus rating of "Hold" from the ten research firms that are covering the company, Marketbeat Ratings reports. Ten research analysts have rated the stock with a hold rating. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $10.80.

Several equities analysts have issued reports on the company. Guggenheim set a $8.00 price objective on Vigil Neuroscience and gave the stock a "neutral" rating in a report on Thursday, May 22nd. Wedbush downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and dropped their price target for the stock from $13.00 to $8.00 in a research report on Thursday, May 22nd. HC Wainwright downgraded Vigil Neuroscience from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $14.00 to $8.00 in a research report on Tuesday, May 27th. William Blair downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd.

Institutional Trading of Vigil Neuroscience

Several large investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC grew its holdings in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after buying an additional 8,358 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Vigil Neuroscience during the fourth quarter valued at about $83,000. Barclays PLC grew its holdings in shares of Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares during the last quarter. Northern Trust Corp boosted its holdings in Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after purchasing an additional 14,572 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after purchasing an additional 49,000 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Stock Down 0.1%

Shares of Vigil Neuroscience stock traded down $0.01 during trading on Friday, reaching $8.06. The company's stock had a trading volume of 383,839 shares, compared to its average volume of 1,134,441. The company has a 50-day simple moving average of $6.61 and a two-hundred day simple moving average of $3.67. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $8.09. The company has a market cap of $384.36 million, a price-to-earnings ratio of -3.93 and a beta of 3.34.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, analysts anticipate that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.